Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 251 to 260 of 1090 total matches.
Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
The American Heart Association has issued its revised guidelines for prevention of infective endocarditis. Antimicrobial prophylaxis for dental procedures is now recommended only for patients at the highest risk of severe consequences from endocarditis who are undergoing the highest-risk procedures. Endocarditis prophylaxis is no longer recommended for gastrointestinal (GI) and genitourinary (GU) procedures. When these changes are implemented, the number of patients receiving antimicrobial prophylaxis to prevent endocarditis should decline sharply.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
(no evidence of risk in humans).
DRUG INTERACTIONS — Des-ciclesonide is metabolized in the liver by CYP3A4 ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
BRCA Screening
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007 (Issue 1274)
: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008 (Issue 1293)
fetal harm) for use in
pregnancy.
DRUG INTERACTIONS — Drug interaction studies
with the combination ...
Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT - Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).
Pantroprazole (Protonix)
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000 (Issue 1083)
to normal within one week after stopping the drug.
DRUG INTERACTIONS — In human studies, no clinically ...
Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • Nov 07, 2005 (Issue 1221)
inhibit platelet aggregation and cause bleeding.
DRUG INTERACTIONS — Clinically significant drug ...
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription.
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005 (Issue 1218)
, but not with the new formulation to date.
DRUG-DRUG INTERACTIONS — Unlike erythromycin
and clarithromycin ...
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.
Tadalafil (Cialis) Once a Day for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Apr 07, 2008 (Issue 1283)
has been taken 3 times a day for up to
a year with no adverse effects.
DRUG INTERACTIONS — PDE5 inhibitors ...
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil (Viagra) and vardenafil (Levitra), the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Dabigatran Etexilate (Pradaxa) - A New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010 (Issue 1351)
also
has some dietary restrictions and has many drug-drug
interactions.1
PHARMACOLOGY — Dabigatran ...
The FDA has approved the oral direct thrombin
inhibitor dabigatran (da big’ a tran) etexilate (Pradaxa –
Boehringer Ingelheim) for prevention of thromboembolic
stroke in patients with non-valvular atrial fibrillation.
It has been available in Canada (Pradax) since
2008 for prevention of thromboembolism in patients
undergoing knee or hip replacement surgery and was
recently approved there for use in atrial fibrillation.
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
The Medical Letter on Drugs and Therapeutics • Jul 22, 2013 (Issue 1421)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1421)
July 22, 2013 ...
The FDA has approved crofelemer (kroe fel’ e mer;
Fulyzaq – Salix), a chloride channel inhibitor derived
from the red sap of the South American plant Croton
lechleri, for symptomatic relief of noninfectious
diarrhea in patients with HIV taking antiretroviral
drugs. It is the first drug approved for relief of antiretroviral-induced diarrhea and the first oral botanical
drug approved by the FDA.